| dc.contributor.author | Ciuleanu, Tudor | |
| dc.contributor.author | Stelmakh, Lilia | |
| dc.contributor.author | Cicenas, S. | |
| dc.contributor.author | Esteban González, Emilio | |
| dc.date.accessioned | 2014-03-14T07:42:41Z | |
| dc.date.available | 2014-03-14T07:42:41Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | Lung Cancer, 71, p. S44-S44 (2011); doi:10.1016/S0169-5002(11)70225-2 | |
| dc.identifier.issn | 0169-5002 | |
| dc.identifier.uri | http://hdl.handle.net/10651/23995 | |
| dc.format.extent | p. S44-S44 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Lung Cancer | |
| dc.rights | © 2011 Elsevier Ireland Ltd. | |
| dc.source | WOS | |
| dc.title | Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (nsclc) with poor prognosis: The phase III Titan study | |
| dc.type | journal article | |
| dc.identifier.local | 20140894 | |
| dc.identifier.doi | 10.1016/S0169-5002(11)70225-2 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1016/S0169-5002(11)70225-2 | |
